Vulvovaginal candidiasis (VVC) is one of the most common fungal infections affecting women of reproductive age. It is primarily caused by Candida albicans and presents with vulval itching, curdy vaginal discharge, burning sensation, dyspareunia, and dysuria. Although uncomplicated infections respond well to antifungal therapy, recurrent or severe disease may significantly impair quality of life and require prolonged management.
We present the case of a 32-year-old female who presented with intense vulval itching, thick white vaginal discharge, dysuria, and discomfort during intercourse for 10 days. Clinical examination, vaginal pH assessment, microscopy, and fungal culture confirmed vulvovaginal candidiasis caused by Candida albicans. The patient was treated with oral fluconazole, topical antifungal therapy, lifestyle modifications, and counseling regarding recurrence prevention, resulting in significant symptomatic improvement.
This case highlights the importance of early diagnosis, identification of predisposing factors, appropriate antifungal therapy, and patient education in the effective management of vulvovaginal candidiasis.
Vulvovaginal candidiasis is a common fungal infection involving the vulva and vaginal mucosa, predominantly caused by Candida albicans. It affects nearly 75% of women at least once during their lifetime, while recurrent vulvovaginal candidiasis occurs in approximately 5–8% of women.
The disease occurs when alterations in the vaginal microenvironment allow overgrowth of Candida species. Factors such as antibiotic use, uncontrolled diabetes mellitus, pregnancy, immunosuppression, hormonal changes, and poor genital hygiene contribute to increased susceptibility.
Several mechanisms contribute to disease development, including:
Important risk factors include:
Common symptoms include:
Early diagnosis and targeted therapy are essential to prevent recurrent infections and improve patient comfort and quality of life.
Patient History
A 32-year-old married female presented to the gynecology outpatient department with:
The patient reported progressive worsening of symptoms over the previous week, causing discomfort during daily activities and sleep disturbance.
History revealed recent antibiotic use for upper respiratory tract infection two weeks earlier.

There was no history of:
The patient had a known history of type 2 diabetes mellitus with irregular glycemic control.
General Examination
Gynecological Examination
Local examination revealed:
No cervical erosion or pelvic tenderness was noted.
Differential Diagnosis
The following conditions were considered:
The presence of intense pruritus, curdy white discharge, erythema, and recent antibiotic exposure strongly suggested vulvovaginal candidiasis.
Investigations
Laboratory Findings
Vaginal pH Testing
Microscopy
Wet mount and potassium hydroxide (KOH) preparation demonstrated:

Fungal Culture
Culture on Sabouraud dextrose agar showed growth of Candida albicans.

Based on clinical presentation, vaginal examination, microscopy findings, and fungal culture, a diagnosis of Acute Vulvovaginal Candidiasis caused by Candida albicans was established.
Initial Management
The patient was counseled regarding:
Medical Management
The patient received:

At 1 Week
At 2 Weeks
At 1 Month
The patient remained under periodic gynecological and diabetic follow-up.

Pathophysiology
Vulvovaginal candidiasis results from overgrowth of Candida species within the vaginal mucosa following disruption of the normal vaginal ecosystem.
Important pathological mechanisms include:
Hyperglycemia enhances fungal proliferation and increases susceptibility to recurrent infection.
Important epidemiological features include:
Common manifestations include:
Vulval itching
Signs commonly observed include:
Diagnosis is primarily clinical but supported by laboratory evaluation.
Important diagnostic modalities include:
Microscopy demonstrating budding yeast cells and pseudohyphae strongly supports diagnosis.
Conservative Measures
Supportive recommendations include:
Pharmacological Therapy
Common antifungal treatments include:
Recurrent infections may require prolonged suppressive antifungal therapy.
Potential complications include:
Untreated recurrent infections may lead to chronic vulvovaginal discomfort.
The prognosis depends upon:
Most uncomplicated cases respond well to standard antifungal therapy.
Vulvovaginal candidiasis is a common fungal infection that can significantly affect comfort, sexual health, and quality of life among women of reproductive age. Early recognition of vulval itching, curdy vaginal discharge, and vaginal irritation is essential for timely diagnosis and treatment.
This case highlights the importance of clinical evaluation, laboratory confirmation, antifungal therapy, glycemic optimization, and patient education in achieving favorable clinical outcomes. Prevention of recurrence through lifestyle modification and management of underlying risk factors remains an essential component of comprehensive care.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Inner Thoughts of Leonard Bernstein, the "Maestro".
2.
Mobile prostate cancer screening clinic can ID the disease in disadvantaged men
3.
No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC
4.
Parents, teachers at Missouri school want answers after string of cancer diagnoses
5.
A promising medication could slow brain tumors in children.
1.
Future-Ready Cancer Screening: What Every Clinician Should Know in 2025
2.
Cancer Evolution and Therapeutic Resistance: Mechanisms, Clinical Insights, and Emerging Strategies
3.
Targeting Cancer Stem Cells in Solid Tumors: Mechanisms, Clinical Implications, and Therapeutic Advances
4.
Partial Gland Ablation in Prostate Cancer: Oncologic Outcomes in Intermediate-Risk Cases
5.
Generative AI for Adaptive Oncology Trial Design
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
5.
Current Scenario of Cancer- The Incidence of Cancer in Men
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation